重组人促红细胞生成素防治早产儿贫血的临床研究

Clinical observation of erythropoietin in prevention of anemia of primaturity

目的探讨重组人类促红细胞生成素(rhEPO)防治早产儿贫血的临床效果。方法 20例早产儿随机分成治疗组和对照组,每组10例。两组均于出生后第2周口服铁剂[元素铁5mg／(kg·d)],观察 4周。治疗组第2周给予rhEPO 700IU／(kg·w),皮下注射,隔日1次,每周3次,共4周。结果治疗前两组间血红蛋白(Hb)、血清转铁蛋白受体(sTfR)、血清铁蛋白(SF)比较均无统计学差异,P>0．05。治疗后治疗组的Hb和sTfR均明显高于对照组(P<0．01和P<0．05),治疗后两组间SF无统计学差异,P>0．05。结论 rhEPO能减轻早产儿贫血的程度,并可能减少输血。

Objective To assess the efficacy of recombinant human erythropoietin (rhEPO) in reducing postnatal hemoglobin decline in premature infants, and in reducing the need for transfusion. Methods A prospective, controlled, randomized trial lasting 4 weeks was performed in 20 clinically stable premature less than 35 weeks' gestation. All participants were randomized to receive 28 days of treatment with daily oral iron 5mg/kg·d and 10 of them (EPO-treated group) with 700U/kg·w of rhEPO. Blood samples were analyzed for hemoglobin(Hb), serum levels of ferritin(SF) and transferring receptor(TfR). Results At the end of treatment, Hb, sTfR were markedly higher in the EPO-treated group, compared with the oral iron group(control group), but SF was lower after treatment in all the babies and existed no difference between control group and EPO-treated group both before and after treatment. Conclusions It is concluded that rhEPO therapy is efficient in pevention of anemia of prematurity with 700U/kg·w rhEPO and it may reduce the need for blood transfusion.